Press Releases

BRIDGEWATER, N.J., Oct. 29, 2015 (GLOBE NEWSWIRE) -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company focused on the needs of patients with rare diseases, today announced that it will release its financial results for the three and nine months ended September 30, 2015, before the opening of the stock market on Friday, November 6, 2015.

Will Lewis, president and chief executive officer, and Andy Drechsler, chief financial officer, will host a conference call for investors beginning at 8:30 a.m. ET on Friday, November 6, 2015 to discuss the third quarter 2015 financial results and to provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing 877-698-3991 (domestic) or 817-522-1636 (international) and referencing conference ID number 67505047. The call will also be webcast live on the internet on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately two hours after its completion through November 20, 2015 by dialing 855-859-2056 (domestic) or 404-537-3406 (international) and referencing conference ID number 67505047. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company focused on the unmet needs of patients with rare diseases. The company is advancing a global phase 3 clinical study of ARIKAYCE™ (liposomal amikacin for inhalation) in nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic infection that can lead to progressive inflammation and lung damage. There are currently no products indicated for the treatment of NTM lung disease in the United States or European Union (EU).  In the EU, the company has filed a marketing authorization application seeking approval of ARIKAYCE for use in patients with NTM. Insmed's earlier-stage pipeline includes INS1009, a nebulized prodrug formulation of treprostinil that the company is developing for the treatment of pulmonary arterial hypertension (PAH), a chronic, life-threatening disorder characterized by abnormally high blood pressure in the arteries between the heart and lungs. To complement its internal research, Insmed actively seeks in-licensing opportunities for a broad range of rare diseases.  For more information, visit www.insmed.com.